FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB | APPRO' |
|---------|--------|
| | |

VAL OMB Number 3235-0287 Estimated average burden hours per response 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | | _ | | | | | | | | | | | | |
|---|----------------------|--|---------------|--------|---|--|--|-------------------------|--|----------|----------------------------|--|--|---|--|--|---------------------------------------|-------------------------------------|
| 1. Name and Address of Reporting Person* KARABELAS ARGERIS N | | | | | 2. Issuer Name and Ticker or Trading Symbol INOTEK PHARMACEUTICALS CORP [ITEK | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner | | | | | |
| (Last) | st) (First) (Middle) | | | | | | | | | | | Officer (give title below) | | | C | other (specify elow) | | |
| 47 HULFISH STREET SUITE 310 | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 02/23/2015 | | | | | | | | | | | | | |
| (Street) | FON N | IJ | 08542 | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) | (\$ | State) | (Zip) | | | | | | | | | | | 7 01111 | med by | WO'C the | an one iv | eporting i croon |
| | | | Table I - | Non- | -Deriv | /ativ | e Se | curities A | cquir | ed, C | Disposed | of, or E | eneficial | ly Owned | | | | |
| Date | | | nsactio | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | | | |
| Common Stock | | | 02/ | /23/20 | 15 | | | С | | 1,394,64 | 5 A (1) | | 1,609,747 | | I | | See Footnotes ⁽¹⁾⁽²⁾⁽³⁾ | |
| Common Stock 02/23 | | | /23/20 | 015 | | С | | 63,560 | A | (4) | 1,673,307 | | I | | See Footnotes ⁽³⁾⁽⁴⁾ | | | |
| Common Stock 02/23/20 | | | /23/20 |)15 | | P | | 603,832 | A | \$6 | 2,277,139 | | I | | See Footnotes ⁽³⁾⁽⁵⁾ | | | |
| | | | Table | | | | | urities Ac s, warran | | | | | | Owned | | , | | |
| Derivative Conversion Date | | 3A. Deemed Execution D if any (Month/Day/ | ate, Transact | | | | 6. Date Exercis Expiration Date (Month/Day/Yea | | ate Securities Underlyii | | s Underlying e Security | | 9. Number of derivative Securities Beneficially Owned Following Reported | tive ties cially d ving | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership ect (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Date Exerci | isable | Expiration Date | Title | Amount o Number o Shares | | | action(s) | | |
| Series AA Convertible Preferred Stock | (1) | 02/23/2015 | | | С | | | 4,459,658 | (1 | 1) | (1) | Commor Stock | 1,394,64 | .5 (1) | | 0 | I | See Footnotes ⁽¹⁾ (2)(3) |
| Convertible Promissory | (4) | 02/23/2015 | | | С | | | \$376,167.93 | (4 | 1) | (4) | Commor | 63,560 | (4) | | 0 | I | See Footnotes ⁽³⁾ |

Explanation of Responses:

- 1. Consists of the following shares of Common Stock issued upon conversion of shares of Series AA Convertible Preferred Stock ("Series AA") and accrued and unpaid dividends thereon, on a 4.05783-for-1 basis, upon the closing of the Issuer's initial public offering: (i) 511,781 shares held directly by Care Capital Investments II, LP ("Care Investments II"), (ii) 35,132 shares held directly by Care Capital Offshore III"). The shares of Series AA had no expiration date.
- 2. Care Capital II, LLC is the general partner of Care Investments II and Offshore II and as a result, Care Capital II, LLC has the ultimate power to vote or direct the vote and to dispose or direct the disposition of such shares. Argeris Karabelas, a member of the Issuer's board of directors, is a managing member of Care Capital II, LLC. Care Capital II, LLC is managed by three or more members and accordingly none of the managing members is deemed to have voting or dispositive control over the securities. Dr. Karabelas disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of his proportionate pecuniary interest therein.
- 3. Care Capital III, LLC is the general partner of Care Investments III and Offshore III and as a result, Care Capital III, LLC has the ultimate power to vote or direct the vote and to dispose or direct the disposition of such shares. Argeris Karabelas, a member of the Issuer's board of directors, is a managing member of Care Capital III, LLC. Care Capital III, LLC is managed by three or more members and accordingly none of the managing members is deemed to have voting or dispositive control over the securities. Dr. Karabelas disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of his proportionate pecuniary interest therein.
- 4. The outstanding principal amount and all accrued and unpaid interest under the Convertible Promissory Notes were automatically converted upon the closing of the Issuer's initial public offering into shares of Common Stock at the initial public offering price of \$6.00 per share. The Convertible Promissory Notes had no expiration date. The number of shares of Common Stock as shown in column 4 of Table I consists of the following: (i) 62,516 shares held directly by Care Investments III, and (ii) 1,044 shares held directly by Offshore III.
- 5. Consists of the following shares purchased at the Issuer's initial public offering: (i) 593,913 shares held directly by Care Investments III, and (ii) 9,919 shares held directly by Offshore III.

Remarks:

/s/ Michael C. Wong, Attorney-in-02/25/2015 Fact for Argeris Karabelas

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.